Heather A. Wakelee
Stanford Medicine · 987 works · 34,503 citations · h-index 87
Top works
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Integrated digital error suppression for improved detection of circulating tumor DNA
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- Lung Cancer Incidence in Never Smokers
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
- Integrating genomic features for non-invasive early lung cancer detection
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
- Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial